reviews in internal medicine year resident 2017 liver...
TRANSCRIPT
Supot Nimanong, MD.
Reviews in Internal Medicine
for 2nd Year Resident 2017
Division of Gastroenterology Siriraj Hospital, Mahidol University
Liver Diseases
Liver diseases
Level 1 • Cholestasis• Portal hypertension• Alcoholic liver diseases• Acute hepatitis• Chronic viral hepatitis• Drug /toxin induced hepatitis• Cirrhosis• NAFLD
Level 2 • Hepatorenal syndrome• Immunologic hepatitis• Hemochromatosis• Liver abscess
Level 3 • Dubin-Johnson syndrome• Gilbert’s disease• Crigger-Najjar syndrome• Rotor syndrome• Cystic diseases of the liver• Veno-occlusive disease• Budd-Chiari syndrome• Osler-Weber syndrome• PBC• Alpha1 antitrypsin deficiency• Wilson disease
Liver diseases
Normal liver
CirrhosisAcute Hepatitis
Chronic Hepatitis
HCC
• Virus• ALD / NAFLD• Wilson disease• Hemochromatosis• Autoimmune • Drugs, toxin• Vascular
• Esophageal varices• Ascites / SBP / hepatic
hydrothorax• Hepatorenal syndrome• Hepatic encephalopathy• HPS / PPHT• HCC
Normal
Cirrhosis
Acute Hepatitis
Chronic Hepatitis
HCCFulminant hepatitis
• HAV, HEV• EBV, CMV, HSV• Ischemic hepatitis• SOS• Hemophagocytosis
• HCV• NASH• Hereditary hemochromatosis
• HBV, HDV• Alcoholic liver diseases • Wilson disease • AIH• Drugs • Budd-Chiari syndrome
HAV HEV HBV HDV HCV
Transmisssion Feco-oral Feco-oral Blood, SexualVertical
HBsAg-dependent
Blood
Presentation Acute AcuteChronic*
AcuteChronic
AcuteChronic Chronic
Risk factors Travel Travel IVDU, tattoo, blood Tx, unsafe sex, family Hx
IVDU IVDU, tattoo, blood Tx
Diagnosis Anti HAV IgM Anti HEV IgMAnti HEV IgG
Anti HBc IgMHBsAg
Anti HDV IgG Anti HCVHCV RNA
Treatment Supportive Ribavirin PegIFNNUCs
IFN IFN + RBVDAAs
Prevention Vaccine 0,6 mo. Vaccine 0,6 mo. Vaccine 0,1,6HBIG
Hepatotrophic viral hepatitis
*AIDS, post organ transplantation
EBV HSV CMV
Host Adolescent ImmunocompromisedPregnancy
Immunocompromised
Symptoms & signs
Mononucleosis-like Skin lesions (50%) Retinitis, colitis, pneumonitis
Diagnosis Blood smearAnti EBV IgM
HSV PCRLiver biopsy
CMV viral loadHistology
Treatment Supportive Acyclovir Ganciclovir
Non-hepatotrophic viral hepatitis
Hepatitis B serology
Interpretation of HBV serology
Setting Anti HBc HBsAg Anti HBs Interpretation
Acute hepatitis
IgM + + - Acute or flared hepatitis B
IgM + - -/+ Severe hepatitis B with spontaneous “S” loss / seroconversion
IgM - + - Flared hepatitis B orCHB with other causes of hepatitis
IgM - - any Other causes of hepatitis
Chronic hepatitis
or check up
IgG + + - Chronic hepatitis B
IgG + - + Prior HBV infection
IgG - - + Post HBV vaccination
IgG + - - Occult HBV, prior HBV infection, pre “S” seroconversion, passive immunization
Phases of chronic HBV infection
0 20 40 60Years
Immune tolerantImmune clearance
HBeAg-positive chronic hepatitis
Inactive carrier state
HBV DNA
Reactivation HBeAg-negative chronic hepatitis
ALT
HBeAg
Anti-HBe
Evaluation of HBsAg+ patient
• HBeAg, anti HBe, (HBV DNA)
• AST, ALT, alb, globStage of disease
• anti HCV, anti HIV, (anti HDV)
• anti HAV IgG
Co-infection &
vaccination
• Ultrasound
• (AFP)Screening
for HCC
Indication for HBV treatment
1. Chronic hepatitis B (both HBeAg+ and HBeAg-)• DNA > 2000 IU/mL, persistent ALT elevation* or significant fibrosis**
*ALT >2x more than 3 months**liver biopsy: F>2 (Metavir), F>3 (Ishak) or fibroscan >7.0 kPa
2. Cirrhosis• Compensated : detectable HBV DNA• Decompensated : HBsAg +
3. HCC: decrease recurrence after curative treatment 4. Prophylaxis
• TACE: HBsAg+• CMT : HBsAg+• Rituximab, SCT : antiHBc IgG+• Post liver transplantation: NUCs + HBIG
5. Decrease vertical transmission: LdT or TDF (GA 24-32 wk until delivery)• Pregnant women : HBV DNA > 2,000,000 IU/ml
Adapted from THASL guideline 2015
HBsAg + HBsAg -, anti HBc +
HBV DNA +
NUCs: LAM, (ETV, TDF) LAM
HBV DNA -
Monitor ALT & HBV DNA
q 1-3 months
RituximabSCT
*After cessation of CMT
HBV DNA < 2000 IU/ml
Pre-emptive treatment for HBV
Adapted from THASL guideline 2015 and EASL guideline 2012
Start
Stop* 6-12 months 12 months
Post exposure prophylaxis for HBV infection
Status Schedule
Unvaccinated HBIG (0.06 ml/kg) + HBV vaccine (3 doses)
Vaccinated• +anti HBs >10 mIU/ml• +anti HBs <10 mIU/ml• -anti HBs
No treatmentHBIG + vaccine 1 dose (booster dose)HBIG 2 doses or HBIG + vaccine 3 doses
Anti HCV
HCV RNA
Interpretation
+ + Chronic hepatitis C
+ - False positiveSVR (post Rx)
- + Acute hepatitis CImmunocompromised host
- - No HCV infection
Hepatitis C serology
Evaluation of anti-HCV+ patients
• HCV RNA (for confirmation)
• HCV genotype (for treatment)HCV
• AST, ALT, alb, glob, CBC
• Liver stiffness, histology, U/SStage of disease
• HBsAg, anti HBs, anti HIV
• Anti HAV IgG
Co-infection
& vaccination
THASL guideline 2015
HBV
• PAN• Glomerulonephritis
Membranous nephropathy MPGN IgA nephropathy
Extrahepatic manifestations
HCV
• Mixed cryoglobulinemia• MPGN• NHL• Porphyria cutanea tarda• Lichen planus• Sjogren syndrome
Risk factors for cirrhosis• Dose: women > 20 g/d, men > 60-80 g/d• Duration: > 10 yearsPE• Common signs: parotid enlargement, Dupuytren’s
contracture, spider neviInvestigations• Megaloblastic anemia• AST > ALT 3x• AST< 500 in alcoholic hepatitis• Imaging: fatty change
Alcoholic liver diseases (ALD)
Alcohol abstinence
Rx alcoholic withdrawal symptoms
Nutritional support
Folic and vitamin supplement
Prednisolone or pentoxifylline for severe alcoholic hepatitis
Management of ALD
Suspected ASH
Severe ASH Mild ASH
mDF* > 32
Lille score at D7
Prednisolone(40 mg daily x 1 wk)
Pentoxifylline*(400 mg tid x 4 wk)
Continue Rx for 3 wk
Stop RxConsider LT
*Severe sepsisActive GI bleeding
Renal failurePancreatitis
or
*mDF, Maddrey’s discriminant function = 4.6 x (PTpatient – PTcontrol) + TB
Non-alcoholic fatty liver disease (NAFLD)
Diagnosis• Metabolic syndrome
: DM, HT, hypertriglyceridemia, obesity• Imaging: fatty liver• Alcohol intake < 20 g/d• Exclude other causes + liver biopsy
NAFLD
Treatment• Rx Comorbid: DM, HT, dyslipidemia• Quit smoking / alcoholic drinking• Weight reduction: goal > 10%
Diet control Exercise Medication Bariatric surgery
• Vitamin E, pioglitazone
Autoimmune hepatitis (AIH)
Clues • Female• Autoimmune diseases
Autoimmune thyroiditis Sjogren syndrome Scleroderma
• High globulin (no cirrhosis)• Responded to steroid treatment
Revised original scoring system of the International Autoimmune Hepatitis Group
Simplified scoring system
Features Score
ANA or SMA 1:40ANA or SMA > 1:80 or anti LKM > 1:40 or SLA +
12
IgG > UNLIgG > 1.1 UNL
12
Viral hepatitis: absence 2
Histology: compatible with AIHtypical AIH
12
• Probable AIH > 6• Definite AIH > 7
Treatment for naïve AIH
Prednisolone• Severe cytopenia• TPMT deficiency• AIH with ALF• Pregnancy• Active malignancy
Prednisolone + Azathioprine• Postmenopausal state• Uncontrolled DM• Severe HT• Obesity• Osteoporosis
Prednisolone < 10 mg/d and/or
Azathioprine 1-2 MKD
Induction
Maintenance
Induction
Maintenance
or
Primary biliary cirrhosis (PBC)
Clues• Middle-aged women• Pruritus, fatigue, scratch marks, (jaundice)• Elevated cholesterol, xanthoma, xanthelasma• Associated autoimmune diseases
: sicca syndrome, autoimmune thyroiditis, RA, scleroderma
Diagnosis of PBC
Elevation of ALP and GGT
Positive AMA(> 1:40)
Histology:Non-suppurative
destructive cholangitis
+
or
Management
Specific treatment• UDCA
Treatments of symptoms and complications• Pruritus• Fatigue• Osteopenia and osteoporosis• Hypercholesterolemia• Fat soluble vitamin supplementation• Portal hypertension
Primary sclerosing cholangitis (PSC)
Clues• Middle-aged men• Recurrent cholangitis, fatigue, pruritus• Associated with IBD (UC > CD)
Diagnosis of PSC
Elevation of ALP and GGT
AbnormalCholangiogram(ERCP, MRCP)
Exclude 2o cause
+
Cause of 2o sclerosing cholangitis
• AIDS cholangiopathy
• Ischemic cholangiopathy
• IgG4 associated cholangitis
• Choledocholithiasis
• Biliary tract neoplasm
• Congenital abnormality of biliary tract
• Biliary tract injury / surgery
Management of PSC
Specific treatment• Dilatation of dominant stricture• No proven medical therapy• Liver transplantation
PBC vs PSC
Features PBC PSC
Sex F M
Chronic cholestasis + +
Associated diseases Sicca, RA, scleroderma,Autoimmune thyroiditis
IBD (UC > CD)
Autoantibody AMA (pANCA)
Cholangiogram Normal Bead-like appearance
Histology Florid duct lesion Onion skin fibrosis
Treatment UDCA Dilation of dominant stricture
Wilson disease (WD)
Clues• Age < 40-50 yr• Acute hepatitis, ACLF, cirrhosis in young
patients• Neurological involvement
Parkinsonism Neuropsychiatric
• KF ring (50-95%), sunflower cataract• Family Hx (AR)
Diagnosis of WD
• Ceruloplasmin
• 24-hr urine copper
• Hepatic copper
• Liver histology
• Brain imaging
• Genetic studies
Diagnostic tests of WD
Tests Normal WD False positive False negative
Ceruloplasmin > 20 mg/dl < 20 mg/dl (S > 90%)
< 5 mg/dl (high Sp)
• Infant, childhood
• End-stage cirrhosis
• NS / PLE
• Copper deficiency
• Menkes disease
• Aceruloplasminemia
• Heterozygote (20%)
• General population (1%)
• Acute inflammation
• Severe liver injury
• Hyperestrogenemia
: pregnancy, pills
Diagnostic tests of WD
Tests Normal WD False positive False negative
Ceruloplasmin > 20 mg/dl < 20 mg/dl (S > 90%)
< 5 mg/dl (high Sp)
• Infant, childhood
• End-stage cirrhosis
• NS / PLE
• Copper deficiency
• Menkes disease
• Aceruloplasminemia
• Heterozygote (20%)
• General population (1%)
• Acute inflammation
• Severe liver injury
• Hyperestrogenemia
: pregnancy, pills
24-hr urine copper < 40 μg > 100 μg (S 77-84%)
• Chronic liver diseases
• Heterozygote (40-70 μg)
• Renal failure
WD with acute liver failure
Tools Sensitivity (%) Specificity (%)
ALP:bilirubin < 4 94 96
AST:ALT > 2.2 94 86
Both 100 100
• F:M = 2:1• Coombs-negative hemolytic anemia: 5-15%• AST&ALT (< 2000 IU/L), AST > ALT• Normal or low ALP (typically < 40 IU/L)
Avoid high copper diet
Medication; D-penicillamine and/or zinc
Rx cirrhotic & neuropsychiatric complications
Consider OLT; ALF, decompensated cirrhosis
Genetic counseling and family screening
Management of WD
Hereditary hemochromatosis (HH)
Clues• Onset: M > 40-50 yr, F > 50-60 yr• Hepatomegaly• Arthropathy (specific: 2nd, 3rd MCP),
diabetes, restrictive cardiomyopathy• Family Hx (AR, AD)
Enterocyte
Macrophage
Ferroportin
Transferrin
HFETfR2HJV
BMPs
Hepcidin
Classification of HH
Type Gene Gene product Inheritance Comment
Type 1HFE-related HH
HFE HFE AR Classic HH
Type 2AJuvenile HHType 2BJuvenile HH
HJV
HAMP
Hemojuvelin
Hepcidin
AR
AR
Younger ageMore severe
Cardiac complicationsHypogonadism
Type 3TfR2-related HH
TfR2 Transferrin receptor2
AR Similar to classic HH
Type 4Ferroportin disease
SCL40A1 Ferroportin AD Less severeAnemia with phlebotomy
Iron study
Transferrin saturation (TS)• Diagnosis: TS > 45% (Sens 98%, NPV 93%)• False positive
22% of heterozygote Secondary iron overload
Serum ferritin (SF)• Diagnosis, marker of fibrosis (>1000 μg/L), monitoring
Diagnosis
HFE geneExclude
secondary HC
Tissue/organ iron overload
Iron study
Liver biopsy
MRI liver
Avoid high ferrous diet
Phlebotomy, (deferoxamine)
EV and HCC surveillance
Consider OLT; decompensated cirrhosis, HCC
Genetic counseling and family screening
Management of HH
WD vs HH
Features WD HH
Mutation ATP7B HFE(C282Y), others
Inheritance AR AR, AD
Penetrance Complete Incomplete (10-15%)
Onset Before 40-50 After 40-50
Hepatic manifestations
Acute on chronic hepatitiscirrhosis
Chronic hepatitiscirrhosis
Other organs involvement
Brain, eye Pancreas, heart, joints
Drug-induced liver injury (DILI)
Mechanisms• Dose dependent: paracetamol• Idiosyncrasy
Immunologic reaction: most drugs Hypersensitivity: allopurinol Autoantibodies (AIH like): minocycline, methyldopa,
diclofenac, atorvastatin
Diagnosis of DILI
1. Temporal relationship
2. Biochemical injury pattern
– Signature drug
– Prior reports / cases
3. De-challenge
4. Re-challenge
5. Exclude other causes
Types of Injury Drugs
Acute hepatocellular injury Isoniazid, rifampicin, ketoconazole, diclofenac etc.
Mononucleosis-like Sulfonamides, phenytoin, dapsone
Bland cholestasis Anabolic/ androgenic steroids
Cholestatic hepatitisChlorpromazine, erythromycin, amoxiclllin-clavulanate,
clarithromycin
Chronic hepatitis Methotrexate, lisinopril
Autoimmune hepatitis Nitrofurantoin, minocycline, methyldopa, diclofenac, atorvastatin
Macrovesicular hepatitis Corticosteroids, methotrexate, asparaginase, alcohol, halothane
Microvesicular hepatitis Valproic acid, tetracyclines, amiodarone, tamoxifen
Cirrhosis Methotrexate, amiodarone
Granulomatous hepatitis Allopurinol, rosiglitazone, sulfonamide, phenylbutazone, quinidine
Primary biliary cirrhosis-like Chlorpromazine, erythromycin, amoxiclillin-clavulanate, haloperidol
Peliosis hepatitis Anabolic steroids, oral contraceptives
Portal vein thrombosis Oral contraceptives
Sinusoidal obstructive syndrome Pyrrolozidine alkaloids, adriamycin, floxuridine, oncotherapy
Hepatic adenoma Anabolic and contraceptive steroids
Pattern• Single overdose – exceed 20 g• Therapeutic misadventure
Risk factors• Malnourished• Heavy alcoholic drinkers• CYP P450 inducers: phenobarbital, phenytoin, isoniazid, zidovudine
Antidote: N-acetylcysteine (NAC)
Paracetamol poisoning
Statins
Features Frequency Comment
Asymptomatic ALT elevation
0.1-3% Dose dependent, class effect
Significant hepatitis Very rare May be seen in combination with other medications
Fulminant hepatitis Extremely rare Risk: 2 in 1 million
AIH like Case report Risk: genetically susceptible individuals
• Compensated cirrhosis is not contraindicated• Can be prescribed safely to NAFLD patients
Antituberculous drugs
Onset: 2 weeks – 14 months
Prevalence • Mild elevation of transaminase 10%• Jaundice 1%
INH, PZA• Idiosyncratic: hepatocellular injury
Rifampicin• Physiologic: indirect hyperbilirubinemia• Hypersensitivity• CYP P450 inducer: enhance INH toxicity
Amoxicillin clavulanate
Onset: 1-3 weeks, may be later than 6 weeksHepatocellular injury (1/3)
• Younger patients• Shorter duration of drug use (1 week)• HLA A*3002, HLA B*1801
Cholestasis (1/3) + mixed pattern (1/3)• Older patients• Longer duration of drug use (2 weeks)• HLA DRB1*1501-DQB1*0602
Lucena MI, et al. Hepatology 2006
Portal Vein Thrombosis
Budd-Chiari Syndrome
Sinusoidal ObstructionSyndromex
x
x
Acute PVT Chronic PVT
Portal biliopathy
Varicealbleeding
Recurrent thrombosis
Complete recanalization
Death
SMV thrombosis
Bowel ischemia
abdominal pain fever
Acute PVT Chronic PVT
CT scan
Causes of PVT
Prothrombotic disorders %
Myeloproliferative diseasesAntiphospholipid syndromePNHBehcet’s diseaseFactor V Leiden mutationFactor II mutationProtein C deficiencyProtein S deficiencyAnti-thrombin III deficiencyPlasminogen deficiencyPregnancyOral contraceptive useHyperhomocysteinemiaTT677 MTHFR genotype
30-406-190-2
0-316-32
14-400-262-300-260-6
6-4012
12-2211-50
Local factors %
CancerCirrhosisInfection / inflammationSurgeryTrauma
2417-225-175-300-3
2/31/3
Causes of PVT
• Malignant tumors of liver1
• Cirrhosis2
• Pylephlebitis3
• Prothrombotic states4
Investigations for prothrombotic stateProthrombotic Investigations
Myeloproliferative neoplasm V617F JAK2 mutation (80% in PV, 50% in ET and PMF)
BM biopsy (normal CBC 40%)
PNH CD55- and CD59-deficient clone at flow cytometry
Ham–Dacie and sucrose tests
Behcet’s disease Conventional criteria + IVC thrombosis
Antiphospholipid syndrome Anticardiolipin Ab or LA or antiß2 glycoprotein 1 Ab
Antithrombin deficiency Antithrombin level
Protein C deficiency Protein C level
Protein S deficiency Protein S level
*Pills, preganancy; cofactors
• Start with LMWH
• Change to warfarin, keep INR 2-3
• Duration: – At least 3-6 months
– long term* in prothrombotic state, SMV thrombosis
Anticoagulation
ATBSurgery
Thrombolytic, TIPS
(Warfarin)
ERCP
BB, EVL
Acute PVT Chronic PVT
Portal biliopathy
Varicealbleeding
Recurrent thrombosis
Complete recovery
Death
xAsymptomatic20%
Acute BCS20%
Chronic BCS60%
IVC thrombosis Fulminant BCS
Budd-Chiari syndrome (BCS)
x x• Jaundice• Tender hepatomegaly• Ascites: wide SAAG, high protein
Cirrhotic complications
CT scan
• Heterogeneous enhancement***
• Caudate lobe hypertrophy
• Thrombus, collateral circulation
• Splenomegaly, ascites
Early central enhancement Delayed peripheral enhancement
Flip flop phenomenon
Causes of BCSProthrombotic disorders %
Myeloproliferative diseasesAntiphospholipid syndromePNHBehcet’s diseaseFactor V Leiden mutationFactor II mutationProtein C deficiencyProtein S deficiencyAnti-thrombin III deficiencyPlasminogen deficiencyPregnancyOral contraceptive useHyperhomocysteinemiaTT677 MTHFR genotype
40-504-250-4
0-336-325-7
10-307-200-230-4
6-126-6037
12-22
Local factors
IVC webMalignancies• HCC• RCC• Adrenal carcinoma
Acute phase
Treatment of BCS
AngioplastyLocal thrombolysis
Stent
Rx prothromboticcondition
Malignant transformation
LMWH
Warfarin
TIPS
Liver transplantation
Rx cirrhotic complicationsSurveillance for EV & HCC
Long term
Sinusoidal obstruction syndrome (SOS)
Drugtoxic agents
TNF
IL1 IL2
• Jaundice• Tender hepatomegaly• Ascites, edema, weight gain
CT scan
• Hepatosplenomegaly
• Ascites
• Patchy liver enhancement
• Patent hepatic vein & IVC
Treatment of SOS
• Symptomatic treatment Low salt diet Diuretics Renal & respiratory support
• Defibrotide• t-PA + heparin• Liver transplantation
Laurie D. DeLeve, et al. Hepatology 2009
Summary
PVT BCS SOS
Presentation• Acute
• Chronic
Abdominal pain + fever
EV, portal biliopathy
Jaundice, ascites,tender hepatomegalyCirrhotic complications
Tender hepatomegaly, ascites, edema, wt. gain, (jaundice)
Common Causes HCC, cirrhosisProthrombotic states
Prothrombotic states PBSCT, CMT
Investigations Doppler US, CT, (Prothrombotic states)
Treatment Anticoagulant• Acute symptomatic PVT• Chronic PVT
(Prothrombotic state, SMV involvement)
Long term anticoagulant Symptomatic Rx
Liver diseases unique to pregnancy
Features Hyperemesis gravidarum
Intrahepaticcholestasis
HELLP Acute fatty liver of pregnancy
Trimester 1 2, 3 3 3
Symptoms N/V, weight loss Pruritus N/V, RUQ pain Hepatitis with coagulopathy
Elevated AST & ALT < 10x 2-10x Severe Moderate to severe
Jaundice Rare < 5 mg/dl Uncommon > 5 mg/dl
Treatment Supportive UDCA Prompt delivery Prompt delivery
Recurrence Possible 60-70% ? 20-70%
Features Hemangioma FNH Adenoma
Prevalence 1-2% 0.01% 0.001%
Sex Female
OCP use - ? Yes
Size Small Small May be large
Number Single
U/S Hyper Slightly hyper/hypo
Slightly hyper/hypo/iso
Arterial enhancement
Peripheral nodular Homogeneous Heterogeneous
Venous Progressive enhancement
Isodensity Isodensity
Other feature - Central scar Fat, hemorrhage
Association Osler-Weber-Rendudisease
Klippel-Trenaunay Type I glycogen storage disease
Characteristics of benign liver tumors
Zakim and Boyer’s Hepatology 6th Edition 2012,Schiff’s Diseases of The Liver, 11th edition 2012Clinical Gastroenterology and Hepatology, 2nd edition 2012
Hemangioma
Incontinuous, peripheral
nodular enhancement
Progressive enhancement
with centripetal filled-in
Kim T et al. Radiology 2001
FNH
Homogeneous arterial
enhancement, sparing the central scar
Isodensity to liver parenchyma
Hepatic adenoma
Heterogeneous arterial enhancement
Heterogeneous mass:fat, hemorrhage
HCC
Arterial enhancement Venous wash out
sensitivity 90%, specificity 95%: Cirrhotic liver or HBsAg+
Risk factors for HCC in Asia
60%
5%
15%
20%HBV
Others
Alcohol
HCV
Bosch FX, et al. Gastroenterology 2004.
Pathogenesis of HCC
Chronic hepatitis
Cirrhosis
HCC
Hepaticadenoma
HBV
Aflatoxin
NASH Wear & tear
HBx
p53
PNPLA3?
Beta catenin
HCC surveillance
Bruix J, Sherman M. Hepatology 2010
EASL-EORTC guidelines 2012
High risk group
Cirrhotic patients• Child-Pugh A and B• Child-Pugh C awaiting liver transplantation
HBV• Age; M>40, F>50• Family history of HCC
HCV• F3 fibrosis
Mass on surveillance ultrasound*
No
Arterial enhancement AND venous wash out
4-phase MDCT/dynamic contrast enhanced MRI
Repeat U/S next 3 months
Growing/changingcharacter
Stable
< 1 cm > 1 cm
No
Yes
BiopsyYesHCC
Other study(CT or MRI)
Arterial enhancementAND venous wash out
Bruix J, Sherman M. Hepatology 2010*in a cirrhotic or HBsAg+ liver
HCC
Compensated Decompensated
Early Intermediate Early
Supportive
Main PV Metastasis
Resection
RFA, OLT
TACE TARE
Sorafenib
PF 0-2
No PHT PHT
OLT
Cirrhosis
No cirrhosis
Early Intermediate Main PV Metastasis
TARE
SorafenibResection
RFA TACE
Early HCC• 1 lesion < 5 cm • 3 lesions < 3 cm
Normal Cirrhosis HCCChronic hepatitis
Prevention of HCC
EASL-EORTC guidelines 2012
Recurrence
HBV & HCV: antiviral treatment (1A)NASH: metformin, statin
HBV : NUCs • HBV vaccination: newborn & high risk groups (1A)
• Avoid risk factors: HBV, HCV, obesity, alcohol (1A)
• Control metabolic conditions : i.e. DM (2A)
Good Luck